JW (CAYMAN) THERAPEUTICS CO. LTDJW (CAYMAN) THERAPEUTICS CO. LTDJW (CAYMAN) THERAPEUTICS CO. LTD

JW (CAYMAN) THERAPEUTICS CO. LTD

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪589.92 M‬HKD
−1.67HKD
‪−848.63 M‬HKD
‪192.11 M‬HKD
‪321.55 M‬
Beta (1Y)
1.42
Employees (FY)
398
Change (1Y)
−130 −24.62%
Revenue / Employee (1Y)
‪61.80 K‬HKD
Net income / Employee (1Y)
‪−272.99 K‬HKD

About JW (CAYMAN) THERAPEUTICS CO. LTD


CEO
MIn Liu
Headquarters
Shanghai
Founded
2017
FIGI
BBG00XXS5DK3
JW (Cayman) Therapeutics Co. Ltd. is a clinical stage cell therapy company, which focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. The company was founded by Yi Ping Li on September 6, 2017 and is headquartered in Shanghai, China.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of 2126 is 1.38 HKD — it has decreased by −1.41% in the past 24 hours. Watch JW (CAYMAN) THERAPEUTICS CO. LTD stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on HKEX exchange JW (CAYMAN) THERAPEUTICS CO. LTD stocks are traded under the ticker 2126.
2126 stock has fallen by −0.71% compared to the previous week, the month change is a −26.32% fall, over the last year JW (CAYMAN) THERAPEUTICS CO. LTD has showed a −46.51% decrease.
We've gathered analysts' opinions on JW (CAYMAN) THERAPEUTICS CO. LTD future price: according to them, 2126 price has a max estimate of 2.40 HKD and a min estimate of 2.40 HKD. Watch 2126 chart and read a more detailed JW (CAYMAN) THERAPEUTICS CO. LTD stock forecast: see what analysts think of JW (CAYMAN) THERAPEUTICS CO. LTD and suggest that you do with its stocks.
2126 reached its all-time high on Feb 22, 2021 with the price of 52.80 HKD, and its all-time low was 1.19 HKD and was reached on Sep 11, 2024. View more price dynamics on 2126 chart.
See other stocks reaching their highest and lowest prices.
2126 stock is 1.45% volatile and has beta coefficient of 1.42. Track JW (CAYMAN) THERAPEUTICS CO. LTD stock price on the chart and check out the list of the most volatile stocks — is JW (CAYMAN) THERAPEUTICS CO. LTD there?
Today JW (CAYMAN) THERAPEUTICS CO. LTD has the market capitalization of ‪574.53 M‬, it has increased by 2.80% over the last week.
Yes, you can track JW (CAYMAN) THERAPEUTICS CO. LTD financials in yearly and quarterly reports right on TradingView.
JW (CAYMAN) THERAPEUTICS CO. LTD is going to release the next earnings report on Mar 19, 2025. Keep track of upcoming events with our Earnings Calendar.
2126 earnings for the last half-year are −0.62 HKD per share, whereas the estimation was −0.69 HKD, resulting in a 9.38% surprise. The estimated earnings for the next half-year are −0.71 HKD per share. See more details about JW (CAYMAN) THERAPEUTICS CO. LTD earnings.
JW (CAYMAN) THERAPEUTICS CO. LTD revenue for the last half-year amounts to ‪93.28 M‬ HKD, despite the estimated figure of ‪115.74 M‬ HKD. In the next half-year revenue is expected to reach ‪141.59 M‬ HKD.
2126 net income for the last half-year is ‪−260.36 M‬ HKD, while the previous report showed ‪−418.72 M‬ HKD of net income which accounts for 37.82% change. Track more JW (CAYMAN) THERAPEUTICS CO. LTD financial stats to get the full picture.
No, 2126 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 14, 2024, the company has 398.00 employees. See our rating of the largest employees — is JW (CAYMAN) THERAPEUTICS CO. LTD on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. JW (CAYMAN) THERAPEUTICS CO. LTD EBITDA is ‪−449.36 M‬ HKD, and current EBITDA margin is −276.69%. See more stats in JW (CAYMAN) THERAPEUTICS CO. LTD financial statements.
Like other stocks, 2126 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade JW (CAYMAN) THERAPEUTICS CO. LTD stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So JW (CAYMAN) THERAPEUTICS CO. LTD technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating JW (CAYMAN) THERAPEUTICS CO. LTD stock shows the sell signal. See more of JW (CAYMAN) THERAPEUTICS CO. LTD technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.